Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scan may spot hidden blood-flow changes that signal glaucoma risk in diabetes

NCT ID NCT07722910

Recruiting now Knowledge-focused Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This observational study uses a painless, non-invasive eye scan called iris OCTA to measure blood flow in the iris of people with type 2 diabetes. Researchers want to see if blood-flow patterns differ between healthy eyes, diabetic eyes without complications, and those with diabetic retinopathy or neovascular glaucoma. The goal is to find out whether iris blood flow can help identify neovascular glaucoma earlier.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If iris blood flow patterns reliably identify neovascular glaucoma early, this could lead to a non-invasive screening tool for diabetic eye complications.
What could go wrong
This is an observational study, not a treatment trial. It may not prove that iris OCTA is accurate enough for routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy neovascular glaucoma type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR GLAUCOMA TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250012, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.